Reported phosphatidylserine (PS) benefits are mixed for memory, with preliminary changes limited to acute stress responses. Results depend on the preparation tested, the study population, and the outcome measured. For product development, the declared PS amount alone does not establish equivalence between ingredients; source and assay specifications also matter.
What Are the Potential Benefits of Phosphatidylserine?
Human studies have focused mainly on three areas:
- Memory and cognitive performance: Some trials reported improvements in selected memory or cognitive measures in older adults, while others found no significant advantage over placebo. Findings vary by study population and PS preparation.
- Acute stress responses: Small studies have reported changes in cortisol, ACTH, or psychological distress during laboratory stress tests. These findings do not establish that PS relieves chronic stress, and results from a phosphatidic-acid/PS complex cannot be attributed to PS alone.
- Exercise-related hormonal responses: One small study reported lower cortisol responses after cycling in men taking PS. It did not establish improved muscle recovery, strength, or endurance.
Evidence does not establish a reliable sleep benefit or support PS as a treatment for cognitive disorders, ADHD, or depression. The sections below examine what the individual studies found and how far their results can be applied.
Does Phosphatidylserine Support Memory and Cognitive Function?
A 2022 systematic review and meta-analysis included nine studies and 961 older adults: five randomized trials and four pre–post studies. Doses were 100–300 mg a day, and durations were 6 weeks to 6 months. Five studies were rated low risk of bias and four had some concerns. The authors reported a positive pooled effect on memory in older adults with cognitive decline. The review combined different designs and phosphatidylserine preparations, so the pooled result does not show that every ingredient or formula produces the same effect. [1]
Soy-Derived PS: Mixed Findings in Older Adults
In a 6-month randomized trial, 78 Japanese adults aged 50–69 with memory complaints took soy-derived phosphatidylserine at 100 mg a day, 300 mg a day, or placebo. Neuropsychological scores rose in every group, including placebo. In a subgroup with relatively low baseline scores, memory scores improved from baseline in the phosphatidylserine groups and did not improve from baseline in the placebo group. The change was associated mainly with delayed verbal recall. Although those lower-scoring phosphatidylserine subgroups improved from their own baselines, scores also increased across the full sample, including placebo. The subgroup finding does not establish a benefit across all participants. The investigators reported no side effect attributed to the soy-derived material. [2]
A 12-week randomized trial enrolled 120 adults older than 57 who met criteria for age-associated memory impairment. Soy-derived phosphatidylserine at 300 mg a day, the same material at 600 mg a day, and placebo were compared, with a further 3-week washout. The trial found no significant differences between the phosphatidylserine and placebo groups on delayed recall and recognition. The result did not change when baseline severity of memory complaints was considered. [3]
Bovine-Cortex PS: Findings from Earlier Trials
Two earlier randomized trials investigated bovine-cortex-derived phosphatidylserine, a preparation distinct from the soy- and sunflower-derived ingredients commonly discussed in contemporary supplement formulations. In 149 adults with age-associated memory impairment, 300 mg a day for 12 weeks was associated with greater improvement than placebo on selected learning and memory measures. Participants with lower performance before treatment were the most likely to respond. [4] In 494 adults aged 65–93 with moderate to severe cognitive decline, 300 mg a day for 6 months was associated with greater improvement than placebo on selected behavioral and cognitive measures. Sixty-nine participants left before 6 months. The investigators reported that the material was well tolerated. [5]
What the FDA and EFSA Assessments Conclude
FDA’s 2003 enforcement-discretion letter, updated in 2004, states that there is not significant scientific agreement that phosphatidylserine reduces the risk of dementia or cognitive dysfunction in the elderly. Most of the evidence FDA reviewed did not support that relationship. The portion described as supportive is very limited and preliminary, and FDA concludes that there is little scientific evidence for the claim. Enforcement discretion applies to a qualified claim about soy-derived phosphatidylserine of very high purity. The claim has to use the specified wording, with the required disclaimer immediately adjacent to it, in the same type size, typeface, and contrast. [6]
The qualified claim cannot identify a specific phosphatidylserine dose as effective for reducing dementia or cognitive-dysfunction risk. That restriction concerns the health claim, not the quantitative ingredient declaration on the Supplement Facts panel. Assay and soy source for a specification are set out for soy-derived phosphatidylserine specified by assay. [6]
In its 2010 assessment, the European Food Safety Authority concluded that the phosphatidylserine preparations covered by the submitted claims were not sufficiently characterised, and that a cause-and-effect relationship had not been established for the claimed cognitive and stress-related effects. The opinion evaluates those claims and the evidence submitted with them. [7] The European Union register lists the cognitive-function claims as non-authorised. [8]
Can Phosphatidylserine Affect Acute Stress and Cortisol Responses?
Cortisol Responses to Mental Stress
In an 80-person trial, a soy-lecithin complex containing phosphatidic acid and phosphatidylserine was taken for three weeks before a Trier Social Stress Test. In the 400 mg/day group, ACTH and cortisol responses were lower, and distress decreased after the test, whereas distress increased in the placebo group. The same hormone pattern was not observed at 600 or 800 mg/day. Heart rate did not differ. Each dose group had 20 people. Because the intervention combined two phospholipids, the result belongs to the complex. [10]
A separate 42-day trial in 16 healthy adults measured electroencephalography before and after a mental stressor. The reported difference was lower beta-1 power in a right frontal region, described by the authors as a more relaxed cortical state. Cortisol was not an outcome in that study. [9]
Cortisol Responses to Exercise
Ten healthy men took 600 mg phosphatidylserine a day or placebo for 10 days, then completed 15 minutes of incremental cycling. Peak cortisol was about 39% lower, and the cortisol area under the curve about 35% lower, than with placebo. The testosterone-to-cortisol area under the curve was higher. Lactate and growth hormone did not differ. The reported outcomes were those hormones during and after the ride. The study did not establish a change in muscle recovery, strength, or endurance. [11]
These studies are preliminary evidence that certain phosphatidylserine-containing preparations can change an acute hormone or distress response to a stressor.
Why Do Phosphatidylserine Study Results Differ?
Inconsistent results are not explained by source alone. The enrolled population, sample size, duration, dose, and endpoint also differ.
Ingredient Source and Composition
Phosphatidylserine preparations are not necessarily interchangeable. EFSA noted differences in fatty-acid composition between animal- and plant-derived phosphatidylserine, and uncertainty in generalising findings from bovine-cortex material to soy-based preparations. [7] An HPLC assay quantifies phosphatidylserine content. It does not by itself establish the same fatty-acid composition or the same accompanying phospholipids as the material in a trial. Sunflower-derived phosphatidylserine was not the test material in the trials discussed here. Ingredient-source distinctions are described under phosphatidylserine sources and types.
Participant Selection and Baseline Scores
The trials enrolled different groups, from adults with memory complaints to older adults with more pronounced cognitive decline, and to healthy men in a cycling test. A change concentrated in one baseline subgroup does not describe the full sample, and it does not extend to people who were not enrolled. [2][3][5][11]
Study Design, Endpoints, and Duration
Memory studies scored recall or broader rating scales over weeks to months. The acute-stress studies scored cortisol, ACTH, or distress during a laboratory stressor, or cortical activity on EEG. A change on one of those endpoints does not transfer to a different source, dose, or product claim. [2][9][10][11]
What Does the Evidence Not Establish?
The available studies do not establish a consistent benefit across phosphatidylserine preparations, populations, or outcomes. Evidence for an acute hormone response should not be read as improved chronic stress, sleep, or athletic recovery. The findings also do not establish phosphatidylserine as a treatment for Alzheimer’s disease, attention-deficit hyperactivity disorder, or depression.
Frequently Asked Questions About Phosphatidylserine Benefits
How strong is the evidence for phosphatidylserine?
Memory results in older adults are mixed: one soy-derived trial described a baseline-linked recall change, another found no difference from placebo, and earlier positive cognitive trials used bovine-cortex material. Acute hormone changes come from small studies, including one that tested a phosphatidic-acid complex rather than phosphatidylserine alone. [2][3][10]
Can a result from one phosphatidylserine preparation be applied to another?
No. Bovine-cortex material, soy-derived phosphatidylserine, and a phosphatidic-acid complex are different test articles. An assay percentage does not show that a new lot matches the fatty acids or the other phospholipids in the trial material. Sunflower-derived phosphatidylserine was not the test article in these trials. [7]
Why do some people report better sleep while others report insomnia?
Personal reports are not controlled trials. The studies above did not measure overnight sleep, so they do not show a sleep benefit or an insomnia rate. A daytime cortisol change is not a sleep result.
Related
Technical and Regulatory References
- Effect of phosphatidylserine on cognitive function in the elderly: a systematic review and meta-analysis. Korean Journal of Food Science and Technology. 2022. Nine studies, 961 participants; five randomized trials rated low risk of bias and four pre–post studies with some concerns; 100–300 mg/day; 6 weeks to 6 months. https://koreascience.or.kr/article/JAKO202210261444695.page
- Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints: a double-blind, randomized, controlled trial. J Clin Biochem Nutr. 2010;47(3):246-255. https://pubmed.ncbi.nlm.nih.gov/21103034/
- Jorissen BL, Brouns F, Van Boxtel MP, et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutr Neurosci. 2001;4(2):121-134. https://pubmed.ncbi.nlm.nih.gov/11842880/
- Crook TH, Tinklenberg J, Yesavage J, et al. Effects of phosphatidylserine in age-associated memory impairment. Neurology. 1991;41(5):644-649. https://doi.org/10.1212/WNL.41.5.644
- Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano). 1993;5(2):123-133. https://pubmed.ncbi.nlm.nih.gov/8323999/
- U.S. Food and Drug Administration. Qualified health claims: letters of enforcement discretion. Phosphatidylserine and cognitive dysfunction and dementia, February 24, 2003; updated November 24, 2004. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/qualified-health-claims-letters-enforcement-discretion
- EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the substantiation of health claims related to phosphatidyl serine. EFSA Journal. 2010;8(10):1749. https://doi.org/10.2903/j.efsa.2010.1749
- European Commission. EU Register of nutrition and health claims. Phosphatidyl serine, entry 1632. Status: non-authorised. https://ec.europa.eu/food/food-feed-portal/screen/health-claims/eu-register/details/POL-HC-7745
- Baumeister J, Barthel T, Geiss KR, Weiss M. Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress. Nutr Neurosci. 2008;11(3):103-110. https://pubmed.ncbi.nlm.nih.gov/18616866/
- Hellhammer J, Fries E, Buss C, et al. Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress. Stress. 2004;7(2):119-126. https://pubmed.ncbi.nlm.nih.gov/15512856/
- Starks MA, Starks SL, Kingsley M, Purpura M, Jäger R. The effects of phosphatidylserine on endocrine response to moderate intensity exercise. J Int Soc Sports Nutr. 2008;5:11. https://pmc.ncbi.nlm.nih.gov/articles/PMC2503954/
Disclaimer
Educational reference only. Not intended to diagnose, treat, cure, or prevent any disease. Dietary supplements are not drugs. FDA’s qualified wording for soy-derived phosphatidylserine is enforcement discretion with a weak-evidence disclaimer. It is not an authorized health claim and not a treatment indication. Brand owners remain responsible for finished-label compliance. KS Nutripharma provides manufacturing feasibility and documentation, not legal or medical approval.
Written by KS Nutripharma Formulation Team | Reviewed by KS Nutripharma Director of R&D (PhD, Food Science | 19+ years nutraceutical development) | Technical review scope: match between the cited trial material and a soy or sunflower specification, and declared phosphatidylserine versus assay. This scope does not cover diagnosis, prescribing, or drug interactions. | Updated October 2026 | About Us
